$3500 | Single User
$7000 | Site License
$10500 | Enterprise License

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H1 2018
[Lowest Price Guaranteed: $3,500]

Published by Global Markets Direct: 27 Feb 2018 | 194818 | In Stock
Related Topics: Bladder Cancer , Breast Cancer , Cancer , Cirrhosis , Colorectal Cancer , Gas , Hepatitis , Hypertension , Immunology , Infectious Disease , Lung Cancer , Multiple Myeloma , Myeloma , Ophthalmology , Pancreatic Cancer , Prostate Cancer , Steatohepatitis

Introduction

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H1 2018

Summary

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Caspase 9 - Pipeline Review, H1 2018, outlays comprehensive information on the Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Caspase-9 is an initiator caspase encoded by the CASP9 gene. Binding of caspase-9 to Apaf-1 leads to activation of the protease which cleaves and activates caspase-3. It is involved in the activation cascade of caspases responsible for apoptosis execution. It promotes DNA damage-induced apoptosis in an ABL1/c-Abl-dependent manner. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular, Gastrointestinal, Genito Urinary System And Sex Hormones, Hematological Disorders, Infectious Disease, Metabolic Disorders, Ophthalmology and Toxicology which include indications Age Related Macular Degeneration, Autoimmune Hepatitis, Bladder Cancer, Breast Cancer, Chemotherapy Induced Neutropenia, Colorectal Cancer, Diabetic Retinopathy, Febrile Neutropenia, Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Hepatitis C, Liver Cirrhosis, Liver Failure (Hepatic Insufficiency), Liver Fibrosis, Liver Transplant Rejection, Metastatic Brain Tumor, Multiple Myeloma (Kahler Disease), Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Islet Transplant Rejection, Portal Hypertension, Prostate Cancer, Renal Failure, Small-Cell Lung Cancer, Solid Tumor and Urinary Tract Cancer.

Furthermore, this report also reviews key players involved in Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62)

- The report reviews Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics and enlists all their major and minor projects

- The report assesses Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H1 2018

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Overview

    Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Therapeutics Development

    Products under Development by Stage of Development

    Products under Development by Therapy Area

    Products under Development by Indication

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Therapeutics Assessment

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Companies Involved in Therapeutics Development

    Bellicum Pharmaceuticals Inc

    BeyondSpring Pharmaceuticals Inc

    Novartis AG

    Pharmedartis GmbH

    Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Drug Profiles

    emricasan - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    flavokawain A - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Fusion Protein to Activate CASP3 and CASP9 for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    MBRI-001 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    plinabulin - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Recombinant Protein to Activate Caspases for Diabetic Retinopathy, Age Related Macular Degeneration and Solid Tumor - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    rimiducid + rivogenlecleucel - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Activate Caspase 8, 9 for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Dormant Products

    Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Discontinued Products

    Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Product Development Milestones

    Featured News & Press Releases

    Feb 05, 2018: BeyondSpring Summarizes Key Messages from KOL Call regarding Lead Asset Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia

    Jan 30, 2018: Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States

    Jan 26, 2018: BeyondSpring Presents Promising Data for Lead Asset Plinabulin at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

    Jan 17, 2018: BeyondSpring to Present Data from Phase 2 Portion of Study 105 Phase 2/3 Trial with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia at 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

    Dec 14, 2017: BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin for the Prevention of Docetaxel Chemotherapy-Induced Neutropenia

    Dec 07, 2017: BeyondSpring to Webcast Key Opinion Leader Event in NYC on Dec. 14, 2017

    Dec 04, 2017: BeyondSpring’s Lead Asset, Plinabulin, Recognized as 2017 National Science and Technology Major Project in China

    Nov 30, 2017: BeyondSpring Initiates Global Phase 2/3 Trial with Plinabulin in China for the Prevention of Chemotherapy-Induced Neutropenia to Demonstrate Superiority

    Oct 26, 2017: BeyondSpring Announces the First Patient Enrolled in China in its Global Phase 2/3 Trial with Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia

    Oct 23, 2017: BeyondSpring Receives Two Grants in China to Further Develop Innovative Drug Pipeline

    Oct 18, 2017: BeyondSpring Chief Medical Officer to Present at the 2017 BIO Investor Forum on Oct. 18 in San Francisco

    Aug 14, 2017: Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis

    Jul 06, 2017: China FDA Approves CTAs for BeyondSpring’s Second Global Plinabulin Registrational Trial for Chemotherapy-Induced Neutropenia Prevention

    Jun 16, 2017: Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference

    Jun 15, 2017: BeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin at 2017 BIO International Convention in San Diego

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

194818 | GMDHC1318TDB

Number of Pages

70

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H2 2017
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 ...
31 Oct 2017 by Global Markets Direct USD $3,500 More Info
Caspase 3 (CPP32, Apopain or YAMA) Activators -Pipeline Insights, 2017
DelveInsight’s, “Caspase 3 (CPP32, Apopain or YAMA) Activators-Mechanism of action Insights, 2017”, ...
01 Sep 2017 by Delve Insight USD $1,250 More Info
Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H2 2017
Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic ...
29 Aug 2017 by Global Markets Direct USD $3,500 More Info
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Pipeline Review, H2 2017
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ce...
18 Jul 2017 by Global Markets Direct USD $3,500 More Info
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H1 2017
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 3.4.22.59) - Pipeline Review, H1 2017SummaryAccor...
20 Jun 2017 by Global Markets Direct USD $3,500 More Info
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Pipeline Review, H1 2017
Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22....
13 Jun 2017 by Global Markets Direct USD $3,500 More Info
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H1 2017
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 ...
30 May 2017 by Global Markets Direct USD $3,500 More Info
Caspase 3 (CPP32, Apopain or YAMA) Activators -Pipeline Insights, 2017
DelveInsight’s, “Caspase 3 (CPP32, Apopain or YAMA) Activators-Pipeline Insights, 2017”, report prov...
30 May 2017 by Delve Insight USD $1,250 More Info
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ced-3 Like Protease or FADD Like ICE or ICE Like Apoptotic Protease 5 or MORT1 Associated Ced 3 Homolog or CASP8 or EC 3.4.22.61) - Pipeline Review, H2 2016
Caspase 8 (Apoptotic Cysteine Protease or Apoptotic Protease Mch 5 or CAP4 or FADD Homologous ICE/Ce...
21 Dec 2016 by Global Markets Direct USD $3,500 More Info
Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H2 2016
Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic ...
16 Nov 2016 by Global Markets Direct USD $3,500 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Caspase 9 (Apoptotic Protease Mch 6 or Apoptotic Protease Activating Factor 3 or ICE Like Apoptotic Protease 6 or CASP9 or EC 3.4.22.62) - Pipeline Review, H1 2018 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...